SCHRODINGER INC

NASDAQ: SDGR (Schrodinger, Inc.)

Kemas kini terakhir: 01 Jun, 1:25AM

21.62

0.18 (0.84%)

Penutupan Terdahulu 21.44
Buka 21.31
Jumlah Dagangan 686,803
Purata Dagangan (3B) 1,199,274
Modal Pasaran 1,586,408,576
Harga / Jualan (P/S) 6.68
Harga / Buku (P/B) 4.15
Julat 52 Minggu
16.60 (-23%) — 28.47 (31%)
Tarikh Pendapatan 6 Aug 2025
Margin Keuntungan -83.39%
Margin Operasi (TTM) -85.45%
EPS Cair (TTM) -2.63
Pertumbuhan Hasil Suku Tahunan (YOY) 62.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 31.15%
Nisbah Semasa (MRQ) 3.45
Aliran Tunai Operasi (OCF TTM) 25.97 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -17.73 M
Pulangan Atas Aset (ROA TTM) -16.27%
Pulangan Atas Ekuiti (ROE TTM) -43.33%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Health Information Services (US) Menaik Bercampur
Health Information Services (Global) Menaik Bercampur
Stok Schrodinger, Inc. Menurun Menaik

AISkor Stockmoo

-1.4
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal -4.0
Purata -1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SDGR 2 B - - 4.15
PGNY 2 B - 38.73 4.04
CERT 2 B - - 1.58
GDRX 2 B - 67.29 2.64
OMCL 1 B - 58.43 1.00
TXG 1 B - - 2.20

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Sektor Healthcare
Industri Health Information Services
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 2.63%
% Dimiliki oleh Institusi 101.86%

Pemilikan

Nama Tarikh Syer Dipegang
Gates Foundation Trust 31 Mar 2025 6,981,664
89.6089.6072.8072.8056.0056.0039.2039.2022.4022.40Harga Sasaran MedianQ4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25Q3 '25Q3 '25
Julat 52 Minggu
16.60 (-23%) — 28.47 (31%)
Median 30.00 (38.76%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Keybanc 14 Jul 2025 30.00 (38.76%) Beli 21.14

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
18 Jul 2025 Pengumuman Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
17 Jul 2025 Pengumuman Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target
27 Jun 2025 Pengumuman Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia
17 Jun 2025 Pengumuman Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12 Jun 2025 Pengumuman Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
29 May 2025 Pengumuman Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing
29 May 2025 Pengumuman Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
23 May 2025 Pengumuman Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22 May 2025 Pengumuman Schrödinger to Present at Jefferies Global Healthcare Conference
20 May 2025 Pengumuman Schrödinger Announces CFO Appointment
14 May 2025 Pengumuman Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
07 May 2025 Pengumuman Schrödinger Reports Strong First Quarter 2025 Financial Results
05 May 2025 Pengumuman Schrödinger to Present at BofA Securities 2025 Healthcare Conference
05 May 2025 Pengumuman AI Healthcare Boom Gains Speed as Regulators and Innovators Align
28 Apr 2025 Pengumuman Schrödinger Presents New Preclinical Data at AACR Annual Meeting
23 Apr 2025 Pengumuman Schrödinger to Announce First Quarter 2025 Financial Results on May 7
Papar semua
22.3522.3521.5521.5520.7520.7519.9519.9519.1519.15Jul 3Jul 3Jul 7Jul 7Jul 8Jul 8Jul 9Jul 9Jul 10Jul 10Jul 11Jul 11Jul 14Jul 14Jul 15Jul 15

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.2000.200-0.000-0.000-0.200-0.200-0.400-0.400-0.600-0.600MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda